Details of the Drug Combination

General Information of Drug Combination (ID: DCH0QWY)

Drug Combination Name
MK-8228 MK-8228
Indication
Disease Entry Status REF
HIV Infections Phase 2 [1]
Component Drugs MK-8228   DMOB58Q MK-8228   DMOB58Q
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-8228
Disease Entry ICD 11 Status REF
Cytomegalovirus Disease 1D82 Approved [2]
Cytomegalovirus infection 1D82 Phase 3 [3]
MK-8228 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cytomegalovirus Terminase (CMV TRM) TTZHSBO NOUNIPROTAC Inhibitor [2]
Cytomegalovirus Terminase UL56 (CMV TRM1) TTOGPL1 TRM1_HCMVA Inhibitor [3]
------------------------------------------------------------------------------------
MK-8228 Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [4]
------------------------------------------------------------------------------------
Indication(s) of MK-8228
Disease Entry ICD 11 Status REF
Cytomegalovirus Disease 1D82 Approved [2]
Cytomegalovirus infection 1D82 Phase 3 [3]
MK-8228 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cytomegalovirus Terminase (CMV TRM) TTZHSBO NOUNIPROTAC Inhibitor [2]
Cytomegalovirus Terminase UL56 (CMV TRM1) TTOGPL1 TRM1_HCMVA Inhibitor [3]
------------------------------------------------------------------------------------
MK-8228 Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04840199) A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93.
4 Pharmacogenetic analysis of OATP1B1, UGT1A1, and BCRP variants in relation to the pharmacokinetics of letermovir in previously conducted clinical studies. J Clin Pharmacol. 2019 Sep;59(9):1236-1243.